Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older
Article first published online: 24 SEP 2013
© 2013 American Cancer Society
Volume 120, Issue 1, pages 43–51, 1 January 2014
How to Cite
Thomsen, F. B., Bandak, M., Thomsen, M. F., Lauritsen, J., Christensen, I. J. and Daugaard, G. (2014), Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older. Cancer, 120: 43–51. doi: 10.1002/cncr.28374
- Issue published online: 17 DEC 2013
- Article first published online: 24 SEP 2013
- Manuscript Accepted: 19 AUG 2013
- Manuscript Revised: 16 AUG 2013
- Manuscript Received: 4 JUN 2013
- germ cell cancer;
- treatment toxicity;
- treatment intensity;
- older patients
Germ-cell cancer (GCC) patients aged ≥40 years have a two-fold higher GCC-specific mortality. It has been hypothesized that reduced treatment intensity combined with increased treatment related toxicity could be the explanation. The objective was to analyze chemotherapy intensity, treatment related toxicity and survival in patients aged ≥40 years treated with standard chemotherapy for GCC compared with a younger control group that received similar treatment during the same period.
From 1984 to 2011, 135 patients aged ≥40 years with disseminated GCC treated with bleomycin, etoposide and cisplatin (BEP). A control-group of 135 patients aged 18–35 years was randomly selected matched on year of BEP treatment. Cumulated doses of BEP as well as bone marrow toxicity, renal- and lung functions were recorded before, during and after termination of treatment. All patients were followed until death or October 1, 2011.
The cumulated doses of BEP were comparable between the two groups, however, more patients aged ≥40 years were reduced in bleomycin doses based on a decrease in carbon monoxide diffusion capacity corrected for haemoglobin (P = 0.03). No differences between the two groups were found regarding bone marrow toxicity or mean percentage changes in lung- or renal function. Patients aged ≥40 year had increased cancer specific mortality, HR = 4.8 (P = 0.005). In particular patients with disease progression after first line chemotherapy had increased mortality (P = 0.015). Moreover, the 5-year overall survival for patients aged ≥40 years was 82.5% compared to the expected 5-year survival of the background population of 96.3% (P <0.001).
Treatment related toxicity could not explain the increased cancer specific mortality in patients aged ≥40 years compared to a younger control-group, and while there were no differences in the administrated doses of cisplatin/etoposide, a decreased number of bleomycin doses were administered in the older patients. Apart from this, the inferior prognosis could be related to tumour biology, increased co-morbidity, or more severe toxicity in relation to second line treatment. Cancer 2014;120:43–51. © 2013 American Cancer Society.